Siemens Healthineers Hires a Google Alum as Tariffs and Debt Cloud the Outlook

Siemens Healthineers made a splash at Berlin’s DMEA healthcare conference this week, unveiling an ambitious artificial-intelligence strategy and a high-profile technology chief. Yet behind the show-floor optimism, the medical-equipment group is grappling with a punishing tariff bill, a weakening diagnostic business, and a looming refinancing challenge that has investors on edge.

Martin Stumpe, a former Google Brain and NASA researcher, will take over as chief technology officer on June 1, replacing Peter Schardt. On the DMEA stage, Stumpe pitched the company’s “Patient Twinning” concept — digital replicas of patients designed to sharpen diagnostic accuracy and, eventually, transform cancer care. The platform is being expanded through five new partnerships on the Teamplay Digital Health Platform Connect, covering areas from wound management to AI-driven clinical decision support.

But the innovation narrative is colliding with a difficult operating reality. In the fiscal first quarter of 2026, revenue edged up 3.8%, yet adjusted earnings per share slipped 3% to €0.49. The diagnostics division shrank 3%, hit hard by an anti-corruption campaign in China that has centralized procurement processes and slowed local sales.

External headwinds are compounding the pressure. New U.S. tariffs are expected to weigh on adjusted EBIT by roughly €400 million this year, while adverse currency effects will add another €200 million to €250 million. Management is sticking to its full-year guidance — comparable revenue growth of 5% to 6% and adjusted EPS between €2.20 and €2.40 — but the path is narrowing.

Should investors sell immediately? Or is it worth buying Siemens Healthineers?

What preoccupies investors even more than the quarterly numbers is the planned spin-off from parent Siemens AG. Once Siemens distributes its 30% stake to its own shareholders, a corporate guarantee covering up to €13.9 billion in Healthineers debt will vanish, forcing the subsidiary to refinance independently. The company had promised concrete details on the process by early in the second calendar quarter of 2026. That deadline has passed.

RBC maintains an “outperform” rating on the stock with a €55 price target, but acknowledges that any prolongation of the separation process could disappoint shareholders. At €36.54, the shares trade roughly 27% below their 52-week high and have barely budged from the year’s low.

There are bright spots beyond the balance sheet. Healthineers is joining Roche and Eli Lilly in a large Alzheimer’s study focused on blood-based biomarkers for earlier detection of neurodegenerative diseases. In the U.S., the company secured a ten-year contract with Arizona’s Onvida Health to replace its entire fleet of imaging and therapy equipment.

All eyes now turn to May 7, 2026, when Healthineers reports second-quarter results. Analysts will be scanning for signs of a recovery in imaging — and, more urgently, for clarity on the spin-off timeline that will determine whether the company can fund its own future.